Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$177.0M
28M shares
52-week range
$4.31 – $9.56
43% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
www.jmcderm.comNo one on the platform currently holds DERM.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 242,500 | $1.1M |
No one on the platform has traded DERM yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$DERM My Q3 revenue early prediction: Emrosi: 10M ($230 ASP) Qbrexza: 7M Accutane: 3M Amzeeq/Zlizi: 1M Eurax: 200k Legacy: 200k Thats 21M revenue. That will definitely develop some FCF and get this moving. Especially with insurance only going to get better.
View on StockTwits ↗$DERM Sure hope I see some insider buying here soon! If not, why not?
View on StockTwits ↗$DERM i guess this stock is too boring for most people. Its too reliable, predictable and a growing cash cow. People want unsafety and adrenaline
View on StockTwits ↗$DERM This should run up hard to Q3 ER. Maybe we see $9.50 again. Potentially the lack of guidance and the low cash balance is preventing a breakout or price stability. But that just gives a golden opportunity to load up.
View on StockTwits ↗$DERM all that great news for a 3.4% gain. total manipulation.staying long
View on StockTwits ↗$DERM IMO, DERM needs another 2 quarters to lock in a consistent trajectory of guidance. ASP needs to notably climb as well as NRX. There has been buyout chatter and ts warranted as Claud has a history of such. So, what would a buyout look like? What should the stock look like? One has to dig into the numbers and reasonable projections over the next 3 years or so. Currently, Emrosi is on a 20% Q/Q upward trajectory. They also are sitting at sub 15k scrips for July. Clearly 20% is about to get shattered. The numbers are screaming 30% right now. Realized pricing should meaningfully increase from $220 to conservatively $250. So, what would be a reasonable guidance for the next 3 years? According to Reuters at FDA approval, Emrosi had a clear shot at taking 1/2 of the addressable market of 1.5 million scrips. At a 20% Q/Q growth clip, that's by 2027/Q4 ER. Just 6 more quarters. That's where I would entertain offers if I was Claud. What would those numbers look like? Cont:...
View on StockTwits ↗$DERM only thing stopping buyout now is patent suit. once settled game on. and it wont be long
View on StockTwits ↗$DERM if what management said about July how Emrosi prescriptions were 14k rx but closer to 15k, that means we could possibly get 45k rx for Q3. Thats 9.9M revenue at current ASP. Huge.
View on StockTwits ↗$DERM HAHAH unreal. But not surprising. When stock went to $9.50 it climbed there on its own without earnings. So in between Q2 and Q3 ER this will organically climb
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.